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Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness
evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccina-
tion, in children60 months of age participating in a prospective cohort study in Bangkok,
Thailand.
Methods
A static decision tree model was constructed to simulate the population of children in the
cohort. Proportions of children with laboratory-confirmed influenza were derived from chil-
dren followed weekly. The societal perspective and one-year analytic horizon were used for
each influenza season; the model was repeated for three influenza seasons (2012–2014).
Direct and indirect costs associated with influenza illness were collected and summed. Cost
of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, adminis-
tration, and supervision cost was added for children who were vaccinated. Quality-adjusted
life years (QALY), derived from literature, were used to quantify health outcomes. The incre-
mental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total
costs between the vaccinated and unvaccinated groups divided by the difference in QALYs
for both groups.
Results
Compared to no vaccination, IIV3 vaccination among children60 months in our cohort
was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained),
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highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the
2014 season (16,200 USD/QALY gained).
Conclusion
The cost-effectiveness of IIV3 vaccination among children participating in the cohort study
varied by influenza season, with vaccine cost and proportion of high-risk children demon-
strating the greatest influence in sensitivity analyses. Vaccinating children against influenza
can be economically favorable depending on the maturity of the program, influenza vaccine
performance, and target population.
Background
Influenza results in a substantial disease burden worldwide and is costly to patients, employers,
and society in terms of medical costs, lost wages, and lost productivity [1]. The most effective
way to prevent illness and severe outcomes from influenza is through vaccination [2]. Influ-
enza vaccines have been used since 1936 and are proven to be safe[3, 4]. The vaccine has been
introduced into many national vaccination programs[4, 5]. In these countries, the World
Health Organization (WHO) recommends national policy makers to take country-specific
information about risk groups, disease burden, and cost-effectiveness into consideration to
help shape the programs[6].
Since 2009, the Government of Thailand has annually purchased seasonal influenza vaccine
for healthcare personnel and high-risk persons including children aged 6 months-2 years[7].
Each year, approximately 3.5 million doses of trivalent inactivated influenza vaccine (IIV3) are
administered free of charge to the estimated 11 million high-risk persons on a first-come, first-
served basis. In 2015, the Health Intervention and Technology Assessment Program of the
Thai Ministry of Public Health published a cost-effectiveness analysis of a hypothetical annual
influenza vaccination program of preschool- and school-aged children with IIV3 or trivalent
live-attenuated influenza vaccine (LAIV)[8]. However, LAIV is not used routinely in Thailand,
and healthy, school-aged children are not included among the recommended risk groups for
influenza vaccination. To date, an economic evaluation of IIV3 among recommended risk
groups administered through the national vaccination program has not been conducted in
Thailand.
In this study, we determined the cost-effectiveness of IIV3 vaccination compared to no vac-
cination in children60 months participating in a cohort study of influenza-associated illness
in Bangkok, Thailand; cost was measured from a societal perspective using a one-year analytic
horizon for each of three influenza seasons.
Methods
Setting
Pediatric Respiratory Infection Cohort Evaluation (PRICE study). A prospective
cohort study (Pediatric Respiratory Infection Cohort Evaluation, PRICE) to determine influ-
enza burden among children living in the Bangkok Metropolitan areas who actively sought
care (for any cause except acute respiratory illness) was established at the Queen Sirikit
National Institute of Child Health (QSNICH; Bangkok)[9]. Enrollment occurred during
August 2011-September 2013; healthy children aged 0–36 months were age- and time-
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matched with “high-risk” children defined as children with underlying conditions (asthma,
prematurity, congenital heart disease, chronic lung or airway disease, abnormality of the upper
airway, kidney disease, liver disease, neurologic/neuromuscular disease, hemoglobinopathy,
metabolic disease, development delay immunosuppressive condition, and cancer). Enrolled
children for whom matches could not be identified were allowed to participate in the study
throughout the course of the study. Written parental informed consent was sought for all chil-
dren. For two years during study follow-up, caregivers were contacted weekly to identify any
acute respiratory illness (ARI) in the 1,149 enrolled children (659 healthy and 490 high-risk)
and encouraged to bring children with ARI to the study clinic to have nasal and throat swabs
collected and tested for influenza by polymerase chain reaction (PCR) at the Armed Forces
Research Institute of Medical Sciences (Bangkok). In this study, the ARI was defined as pres-
ence of2 of the following symptoms according to caregivers’ reports: fever, nasal discharge/
congestion, cough, or sore throat. Of 3,458 ARI episodes identified, 3,078 (89%) were pre-
sented for care at QSNICH. Study staff interviewed caregivers 1–2 weeks following illness
onset about illness management, outcome, and related expenses. Influenza vaccination status
was verified using children’s vaccine cards. The study was approved by the ethics committees
of the QSNICH, with the U.S. Centers for Disease Control and Prevention’s Institutional
Review Board relied on the QSNICH’s determination. Eight laboratory-confirmed influenza
cases (4.9%) were identified among vaccinated healthy children (Hvax) in 2012, 9 cases (5.0%)
in 2013, and 3 cases (3.8%) in 2014. Two influenza cases (1.9%) were identified among vacci-
nated high-risk children (HRvax) in 2012, 9 cases (6.4%) in 2013, and no cases (0%) in 2014.
Thirty-three influenza cases (8.9%) were identified among unvaccinated healthy children (Hun-
vax) in 2012, 35 cases (8.4%) in 2013, and 10 cases (4.7%) in 2014. Sixteen influenza cases
(5.7%) were identified among unvaccinated high-risk children (HRunvax) in 2012, 19 cases
(6.1%) in 2013, and 1 case (0.7%) in 2014. Length of illness (i.e., onset to illness resolution
based on caregivers’ reports) in children with influenza were generally <12 days.
Influenza season and vaccination program in Thailand. Influenza viruses circulate
year-round in Thailand with two peaks (June-November and January-March)[10]. The
national influenza vaccination campaign runs annually during May-July. Therefore, we
defined an influenza season as June through next May (e.g., the 2012 season was June
2012-May 2013)[11]. Influenza vaccine is not part of the routine Expanded Program on
Immunization schedule which comprises the required vaccinations for children in Thailand;
influenza vaccination is based on caregivers’ choice and was not administered as part of the
PRICE study. Proportions of children vaccinated in the PRICE study are shown in Table 1. At
their first vaccination opportunity, children aged <9 years are recommended two doses,28
days apart, for full vaccination; one dose is recommended for subsequent years. Data from
PRICE and other studies in Thailand show the Southern Hemisphere IIV3 was 64% effective
against PCR-confirmed influenza virus infection in young children in 2012, 64% in 2013, and
24% in 2014 seasons[9, 12].
Decision-analytic model
To estimate the cost-effectiveness of IIV3 vaccination among children aged 6–60 months, a
static decision tree model (Fig 1) was constructed to simulate the population of children in our
cohort using TreeAge Pro Suite 2014 (Williamstown, MA). The proportions of children with
influenza, treated in either outpatient (OPD) or inpatient departments (IPD), were derived
from children followed weekly in the cohort (Table 1). Death was not considered in our model
because there were no influenza-related deaths among enrolled children. Analysis was
CEA of influenza vaccination among young children
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PROPORTION OF CHILDREN IN THE COHORT BY VACCINATION AND MEDICAL
CONDITION
Vaccinated group
Healthy 67% 56% 52% PRICE
High-risk 33% 44% 48% PRICE
Unvaccinated group
Healthy 57% 57% 59% PRICE
High-risk 43% 43% 41% PRICE
MEDIAN LENGTH OF ILLNESS IN DAYS 2012 2013 2014
Vaccinated group
Healthy children, sick with influenza and treated in OPD 8.5 8 8 PRICE
Healthy children, sick with influenza and treated in IPD 9 0b n/ab PRICE
High-risk children, sick with influenza and treated in OPD 8.5 8.5 n/ab PRICE
High-risk children, sick with influenza and treated in IPD n/a b 10.5 n/ab PRICE
Unvaccinated group
Healthy children, sick with influenza and treated in OPD 9 8 8 PRICE
Healthy children, sick with influenza and treated in IPD 10 6 21 PRICE
High-risk children, sick with influenza and treated in OPD 8 10 7 PRICE
High-risk children, sick with influenza and treated in IPD 10 12 n/ab PRICE
INFLUENZA VACCINATION 2012 2013 2014
Influenza vaccine uptake 29% 31% 29% PRICE
Proportion of vaccinated children receiving 1 influenza vaccine dose 0.55 0.71 0.88 PRICE
Proportion of vaccinated children receiving 2 influenza vaccine doses 0.45 0.29 0.12 PRICE
MEDIAN COST ASSOCIATED WITH INFLUENZA ILLNESS (USD)a 2012 2013 2014
Vaccinated group
Healthy children, sick with influenza and treated in OPD 23.89 31.17 22.15 PRICE
Healthy children, sick with influenza and treated in IPD 286.14 n/ab n/ab PRICE
High-risk children, sick with influenza and treated in OPD 51.93 27.59 n/ab PRICE
High-risk children, sick with influenza and treated in IPD n/ab 483.68 n/ab PRICE
Unvaccinated group
Healthy children, sick with influenza and treated in OPD 27.97 23.13 30.83 PRICE
Healthy children, sick with influenza and treated in IPD 172.89 94.85 1,011.91 PRICE
High-risk children, sick with influenza and treated in OPD 18.97 21.82 18.77 PRICE
High-risk children, sick with influenza and treated in IPD 241.16 2,848.08 n/ab PRICE
COST OF INFLUENZA VACCINE ADMINISTRATION (USD/dose) 2012 2013 2014
Vaccine cost including storage and vaccine distribution for one IIV3 ready-to-use adult dose
(cost includes half-dose administered to child and half-dose discarded)
3.64 3.68 3.48 NHSO
Cost for promotion, administration, and supervision 0.85 0.86 0.77 NHSO
OUTCOMES 2012 2013 2014
Utility weight for healthy children 0.87 Canaway
et al.[14]
Utility weight for children who were sick with influenza and treated in OPD 0.65 Perlroth et al.
[15]
Utility weight for children who were sick with influenza and treated in IPD 0.50 Perlroth et al.




Healthy children, sick with influenza and treated in OPD 7 9 3 PRICE
(Continued)
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performed by influenza season (2012, 2013, and 2014) because influenza vaccine efficacy
declines after 6–8 months[13].
Perspective and analytic horizon
In this analysis, the societal perspective and one-year analytic horizon were used for each influ-
enza season[16, 17]. Children included in each modeled influenza season were not mutually









Healthy children, sick with influenza and treated in IPD 1 0 0 PRICE
Healthy children, not sick with influenza 154 172 76 PRICE
High-risk children, sick with influenza and treated in OPD 2 7 0 PRICE
High-risk children, sick with influenza and treated in IPD 0 2 0 PRICE
High-risk children, not sick with influenza 103 132 73 PRICE
Unvaccinated group
Healthy children, sick with influenza and treated in OPD 29 34 9 PRICE
Healthy children, sick with influenza and treated in IPD 4 1 1 PRICE
Healthy children, not sick with influenza 337 379 203 PRICE
High-risk children, sick with influenza and treated in OPD 13 17 1 PRICE
High-risk children, sick with influenza and treated in IPD 3 2 0 PRICE
High-risk children, not sick with influenza 265 291 150 PRICE
aTotal cost of illness was a summation of direct medical, direct non-medical, and indirect or opportunity costs associated with influenza illness. The largest
portion of costs among ill children in the cohort were direct costs with only a few cases incurring indirect or opportunity costs; vaccine administration cost
was added for each vaccinated child.
bNo cases
OPD: outpatient department; IPD: inpatient department; NHSO: National Health Security Office; PRICE; Pediatric Respiratory Infection Cohort Evaluation
https://doi.org/10.1371/journal.pone.0183391.t001
Fig 1. A schematic diagram representing the decision tree used in each year of the analysis.
https://doi.org/10.1371/journal.pone.0183391.g001
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Model parameters
Vaccination status and proportion of children by model arm. The proportions of
healthy and high-risk children, children vaccinated, and influenza cases treated in OPD or
IPD were taken from the PRICE study (Table 1). Results of statistical tests of differences across
these populations are reported elsewhere[9].
Cost parameters. Direct costs included medical and diagnostic costs (paid out of pocket
and by health insurance) and transportation costs. Indirect or opportunity costs were self-
reported actual income loss or monetized value of productive work time lost related to care for
ill children. Direct and indirect costs paid by caregivers were collected from post-illness inter-
views and the value of caregiver’s time was calculated using the human capital approach[18].
Caregivers were asked about days they missed work to care for ill children (if they worked),
days the ill children missed daycare (if children went to daycare), and the caregivers’ average
income per day. The indirect costs were calculated by multiplying days of missed work or day-
care (whichever was higher) by the caregiver’s daily income. The time of caregivers who did
not earn income was valued at the government-established minimum wage (300 Baht/day)[16,
17, 19]. Costs paid for by the health insurance system were from the QSNICH’s database.
QSNICH is a public hospital; all medical costs are determined by government regulation
except personnel charges paid by the government as salaries or overtime pay that were not
charged to patients. Therefore, the personnel charges were not included in the analysis.
The annual cost of the vaccine program, obtained from the National Health Security Office
(Nonthaburi, Thailand), included the cost of vaccine purchase, storage, transportation, pro-
motional material, vaccine administration at local hospitals, and program supervision. The
annual national program cost for these elements was divided by the number of doses pur-
chased nationally in that year to derive cost per IIV3 ready-to-use adult dose. For the purpose
of this analysis, the cost of one full IIV3 adult dose was applied for each child who received half
of a ready-to-use adult dose with the other half discarded. The cost of the wasted half-dose was
included in the analysis, but the costs of wastage more generally were not included as no offi-
cial data on national wastage rates were available. Direct and indirect costs were converted
from Thai Baht to US dollars (USD) using the relevant exchange rate (31.1, 30.7, 32.5 Baht to
one USD in 2012, 2013, 2014, respectively)[20]. Median costs per influenza episode were cal-
culated for healthy and high-risk children and vaccinated and unvaccinated groups and used
in the model[21]. No discounting was performed because the analysis was conducted over a
one-year analytic horizon. Spillover costs (e.g., costs associated with time healthcare providers
spent vaccinating children or treating children with influenza and not performing other tasks)
were not considered in the model. Median influenza-associated illness costs ranged from <20
USD in OPD to about 2,850 USD in IPD settings (Table 1).
Quality-adjusted life years and utility weights. Quality-adjusted life years (QALY) were
used to quantify the health outcome of number of days ill with influenza. To determine the
QALY value, the utility weight associated with one of three possible health states—well, ill with
influenza requiring outpatient care, or ill with influenza requiring inpatient care—was multi-
plied by the fraction of a year lived in that state. For each of the four study groups (Hvax,
HRvax, Hunvax, and HRunvax), the median number of days spent in each of the three health
states was calculated from post-illness interview data. Utility weights (i.e., estimates of health-
related quality of life based on how a sample of the general population would trade off years of
full health to avoid years lived with various degrees of disability) for each of the three health
states were drawn from published literature: 0.87 for well children [14], 0.65 for children
mildly sick with influenza and treated in OPD, and 0.50 for children with more severe influ-
enza illness requiring treatment in IPD[15]. For example, for the Hunvax group and the health
CEA of influenza vaccination among young children
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state of influenza illness requiring inpatient care, the median number of days ill was 10 days,
which translates to 0.86 QALY, i.e., [0.50(10 days ill with influenza/365 days per year)+0.87
(355 days not ill with influenza/365 days per year)]. Spillover benefits (e.g., benefits associated
with reduced events of related illnesses such as pneumonia or protecting other high-risk
groups from influenza) were not considered in the model.
Incremental cost-effectiveness ratio
Incremental cost-effectiveness ratios (ICERs) were calculated as the difference in the expected
total costs between the vaccinated and unvaccinated groups divided by the difference in
QALYs between groups. WHO threshold values were used as proxies for the decision maker’s
willingness to pay to determine whether a public health intervention was cost-effective[22].
Compared to no vaccination, influenza vaccination was cost-saving if the ICER was negative,
very cost-effective if the ICER was less than Thailand’s Gross Domestic Product per capita
(GDPpc), cost-effective if the ICER was 1–3 times Thailand’s GDPpc, and not cost-effective if
the ICER was >3 times Thailand’s GDPpc. The World Bank’s GDPpc values for Thailand for
2012, 2013, and 2014 (5,918 USD, 6,229 USD, and 5,977 USD, respectively) were used for com-
paring ICERs against these WHO thresholds[23].
Sensitivity and scenario analyses
For each season modeled, univariate sensitivity analyses were conducted for vaccine cost
(range: 0.5–4 times current price), rate of second IIV3 doses (range: 29–45%), proportion of
high-risk children (range: 0–100%), utility weights (range: 0.73–0.95 for well children, 0.52–
0.66 for children with influenza treated in OPD, and 0.05–0.58 for influenza treated in IPD)
[15, 24–26], and proportion of influenza cases (range: 4.8–5% for healthy vaccinated children,
2.8–6.4% for high-risk vaccinated children, 7.3–8.9% for health unvaccinated children, 4.2–
6.1% for high-risk unvaccinated children). Ranges were selected to reflect programmatically
probable values and available data from the PRICE study or published literature. As utility
weights were drawn from settings outside of Thailand, different combinations of weights from
other literature sources and their averages were also used to calculate QALYs in multivariate
sensitivity analyses. Scenario analyses were also conducted with alternative values for the pro-
portion of high-risk children (10%, 5%) and cost of vaccine (2 and 3 times the current price) to
project cost-effectiveness under implementation conditions beyond the PRICE cohort that
might be encountered by the national influenza vaccine program.
Results
Base case
The expected total costs and QALYs were higher in vaccinated than unvaccinated children
in all modelled seasons (i.e., vaccination was both more expensive and had more beneficial
health outcomes compared to no vaccination). Compared to no vaccination, IIV3 vaccination
among children aged 6–60 months in the PRICE study was not cost-effective in the 2012 sea-
son (ICER: 24,450 USD/QALY gained), highly cost-effective in the 2013 season (ICER: 554
USD/QALY gained), and cost-effective in the 2014 season (ICER: 16,200 USD/QALY gained;
Table 2), based on WHO thresholds. In all seasons, the direct costs associated with healthcare
services accounted for the majority of the costs of illness, while indirect costs associated with
missed work or actual income loss of caregivers were minimal.
CEA of influenza vaccination among young children
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Sensitivity analyses
In univariate sensitivity analyses, the variables with the greatest influence on the ICER were
vaccine cost (2012, 2013, 2014 seasons), utility weight for children without influenza illness
(2012 and 2014 seasons), rate of influenza cases among high-risk vaccinated and unvaccinated
children (2012 and 2013 seasons), and proportion of high-risk children (2013 and 2014 sea-
sons) (Fig 2 and S1 Table). In 2012, IIV3 vaccination became cost-effective in all multivariate
sensitivity analyses of combinations of utility weights, except when utility weights of 0.92 was
used for well children, 0.659 for children with influenza treated in OPD, and 0.514 for children
treated in IPD (S2 Table). In 2013, regardless of the choice of utility weights, IIV3 vaccination
remained highly cost-effective by WHO thresholds compared to no vaccination. In contrast,
mixed results were observed in 2014 with cost-effectiveness strongly influenced by the choice
of utility weight. In 2012, IIV3 vaccination became cost-effective only when the vaccine price
was reduced by half (S2 Table). IIV3 vaccination was not cost-effective in 2012 regardless of
threshold set for high-risk children (0%-100%). IIV3 became cost-effective (cost-saving to
highly cost-effective) in 2013 at all thresholds set for high-risk children (0%-100%). However,
IIV3 was only cost effective (cost-saving to highly cost-effective) only when there was no high-
risk children (0%) or only a small percentage of high-risk children (5%). When the vaccine
price was changed, IIV3 vaccination was cost-saving if the price was reduced by half in both
2013 and 2014 and remained either highly cost-effective or cost-effective if the price was
increased by2 times. Taking all modelled seasons into account, the most favorable scenario
in terms of cost-effectiveness was when vaccine price was reduced by half. The least favorable
scenarios were when the population consisted of 100% high-risk children and when vaccine
price increased to2 times the current price.
Table 2. Results of base case analysis comparing administration of seasonal trivalent inactivated influenza vaccination among children aged60
months to no vaccination, 2012–2014.













6.49; OPD patient COI: 1.02;
IPD patient COI: 1.18)
3.80 (OPD patient COI:
1.63; IPD patient COI:
2.18)




5.84; OPD patient COI: 1.47;
IPD patient COI: 3.00)
9.59 (OPD patient COI:
1.60; IPD patient COI:
7.99)




4.79; OPD patient COI: 0.43;
IPD patient COI: N/A)
3.60 (OPD patient COI:
0.82; IPD patient COI:
2.78)
0.8699 0.8698 16,200 Cost-effective
aExpected value of total cost per child (rounded to the nearest US cent) is the product of the median cost of illness for each health outcome state (not ill with
influenza, ill with influenza requiring outpatient care, ill with influenza requiring inpatient care) for each study group (vaccinated health children, vaccinated
high-risk children, unvaccinated healthy children, unvaccinated high-risk children) multiplied by the proportion of children from the Pediatric Respiratory
Infection Cohort Evaluation study who ended up in each health outcome state in each study group (i.e., the probability of any given child ending up in that
health outcome state, given his or her study group assignment); for vaccinated children, the expected value of total cost also includes the cost of vaccine
administration in addition to the cost of illness.
bThe expected values of quality adjusted life years (rounded to four significant digits) are the products of the magnitude of each health outcome multiplied by
the proportion of children in the Pediatric Respiratory Infection Cohort Evaluation study experiencing that health outcome for each study group and health
outcome state.
Gross Domestic Product per capita: 5,918 USD (2012), 6,229 USD (2013), and 5,977 USD (2014)
QALY, quality adjusted life year; ICER, incremental cost-effective ratio; WHO, World Health Organization; CEA, cost-effectiveness analysis; OPD,
outpatient department; COI, cost of illness; IPD, inpatient department
https://doi.org/10.1371/journal.pone.0183391.t002
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Fig 2. One-way sensitivity analyses. Incremental cost-effectiveness ratios are reported in US dollars per
quality adjusted life year gained. Ranges of values used are as follows: Cost of vaccine, 0.5–4.0 times current
vaccine cost; Utility weight—well children, 0.73–0.95; Utility weight—children with influenza treated in
outpatient department, 0.52–0.66; Utility weight—children with influenza treated in inpatient department,
0.05–0.58; % of second influenza vaccine doses, 0.29–0.45; Proportion of high-risk children, 0–1; % of
influenza cases among unvaccinated high-risk children, 4.2–6.1; % of influenza cases among unvaccinated
CEA of influenza vaccination among young children
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Discussion
Compared to no vaccination, we found that the cost-effectiveness of IIV3 vaccination among
children participating in the PRICE study varied by influenza season. Cost/QALY gained was
lowest in the 2013 season (i.e., most cost-effective) and highest in the 2012 season (i.e., least
cost-effective). Our results were consistent across varying utility weights for the 2012 and 2013
seasons, but not for 2014. In scenario analyses, we found that cost-effectiveness differed
depending on the target population for vaccination and the vaccine price.
The findings from the 2012 model resemble the introduction of an influenza vaccine pro-
gram where the program bears start-up costs, administering two vaccine doses to each child.
Many children in our study required two vaccine doses in 2012 for full vaccination as it was
their first eligible vaccination opportunity although the models for subsequent years also
accounted for the cohort’s new members who required two vaccine doses. As a result, the vac-
cine cost in 2012 was higher than subsequent years. As a vaccination program matures, as illus-
trated by the 2013 and 2014 models, a greater return on investment may be realized depending
largely on how well the vaccines perform and the number of newly eligible children requiring
two vaccine doses for those particular seasons. In 2013, vaccine effectiveness (VE) was 64% [9]
and the intervention was considered highly cost-effective based on ICER thresholds. In 2014,
VE was 24% due to a poor match between the circulating and vaccine strains [12], but the
intervention was still cost-effective due to the lower cost resulting from fewer doses required
to fully vaccinate cohort children. New members entered the cohort only when they sought
care at the study clinic (a children’s hospital without a maternity ward, and therefore without
systematic recruitment of newborns); the share of children requiring two doses of IIV3 in 2013
and 2014 is therefore lower in our analysis than would be expected in a hypothetical national
influenza vaccination program for children aged 6 months-2 years in which roughly half of
each year’s birth cohort would be newly eligible each year.
From a programmatic standpoint, risk group prioritization plays an important role in the
performance of a vaccine program. Our findings suggest that in a hypothetical population con-
sisting of 100% of healthy children or 5% or 10% of high-risk children, but with the same rate
of influenza as observed in the PRICE study, the vaccination program would be generally cost-
effective or cost-saving after an introductory year, due to the higher incidence of influenza in
healthy than in high-risk children observed in the cohort[21]. Notably, in a year with an effec-
tive vaccine, the program was also cost-saving when vaccinating only high-risk children
because of the reduced illness duration among vaccinated children. In our cohort, the inci-
dence of influenza was much higher in healthy than in high-risk children, possibly because
they might have had greater social contact with others (e.g., attending daycare) compared to
high-risk children who tended to stay at home. With limited vaccine supply, our findings
underscore the need to take vaccination target population composition and disease severity
and illness duration into account for vaccine prioritization to maximize health benefits per
administered vaccine dose.
Other studies, mostly conducted in developed countries, have examined the cost-effective-
ness of an influenza vaccine among children. Although one previous modeling study examined
influenza vaccination scenarios for children over two years old in Thailand [8], our study
assessed the cost-effectiveness of vaccinating younger children against seasonal influenza ill-
ness using IIV3 based on empirical cost and outcome data from a cohort study over three
healthy children, 7.3–8.9; % of influenza cases among vaccinated high-risk children, 2.8–6.4; and % of
influenza cases among healthy children, 4.6–5.0. ICER: incremental cost-effectiveness ratio; OPD, outpatient
department; IPD, inpatient department.
https://doi.org/10.1371/journal.pone.0183391.g002
CEA of influenza vaccination among young children
PLOS ONE | https://doi.org/10.1371/journal.pone.0183391 August 24, 2017 10 / 15
influenza seasons. Our findings are consistent with those previously reported from other coun-
tries that influenza vaccination among young children is typically economically advantageous
from a societal perspective[28–32]. The findings highlight that performance of an influenza
vaccine program is closely linked with VE, which varies from year to year depending on the
match of circulating viruses to vaccine strains. Thus, annual program evaluations to assess vac-
cine coverage in target groups and VE are needed for accurate cost evaluations.
Our analysis has a few limitations. High-risk children in the PRICE study were oversampled
and may not reflect the true proportion of high-risk children in the general population, which
was thought to be<10%. We assumed all vaccinated children received the vaccine from the
government and that the standard government payment schedule accurately captured the hos-
pital’s production costs. The observed vaccine wastage rate was high (50%) due to the lack of
ready-to-use pediatric doses in country, resulting in children receiving half of a ready-to-use
adult dose with the other half discarded; while costs of this PRICE study-specific wastage were
included in the analysis (resulting in higher vaccination costs and therefore less favorable
ICERs for vaccination), overall national wastage costs were not included due to lack of official
data (although internal NHSO estimates put such wastage at approximately 5% and therefore
of lesser influence than the study-specific wastage on the vaccination strategy costs). All chil-
dren with ARI in the study were invited to the hospital including those with mild symptoms
who might not require a hospital visit; therefore, the total costs may be higher than what
would be observed in other health care settings. Results are season-specific and should not be
generalized to other influenza seasons. Lastly, our static model, though easy to interpret and
similar to those used to evaluate the cost-effectiveness of influenza vaccination in other settings
[33–36], did not account for the variation and distribution of input parameters (e.g., vaccina-
tion rate, length of illness, cost) that likely exists for the general population of children in Thai-
land beyond the PRICE study and may be sensitive to small cell sizes. This static model also
did not account for indirect benefits of childhood influenza immunization (e.g., reduced influ-
enza transmission in the general population, resulting reductions in influenza cases among
other at-risk populations such as the elderly. Lastly, our study did not capture the side effects
that may occur as a result of vaccination.
In summary, our results suggest that vaccinating young children against influenza can be
economically favorable from a societal standpoint depending on the maturity of the program,
influenza vaccine performance, and target population. Our findings presented as dollars per
QALY gained allows policymakers to compare the cost-effectiveness of influenza vaccination
of children with other potential investments in preventive health services.
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S1 Table. Parameters used in one-way sensitivity analyses.
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S2 Table. Results of one-way sensitivity analysis and scenario analysis comparing admin-
istration of seasonal trivalent inactivated influenza vaccine among children aged60
months to no vaccination, 2012–2014. aExpected value of total cost per child (rounded to
the nearest US cent) is the product of the median cost of illness for each health outcome state
(not ill with influenza, ill with influenza requiring outpatient care, ill with influenza requir-
ing inpatient care) for each study group (vaccinated healthy children, vaccinated high-risk
children, unvaccinated healthy children, unvaccinated high-risk children) multiplied by the
proportion of children from the PRICE study who ended up in each health outcome state in
each study group (i.e., the probability of any given child ending up in that health outcome
state, given his or her study group assignment); for vaccinated children, the expected value
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of total cost also includes the cost of vaccine administration in addition to the cost of illness.
bThe expected values of QALYs (rounded to four significant digits) are the products of the
magnitude of each health outcome multiplied by the proportion of children in the PRICE
study experiencing that health outcome for each study group and health outcome state.cChil-
dren with underlying medical condition e.g., prematurity, congenital heart disease, chronic
lung or airway disease, neuromuscular disease. High-risk children in the PRICE cohort were
oversampled to about 40% of the entire sample. dDifference at >4 significant digits. Gross
Domestic Product per capita: 5,918 USD (2012), 6,229 USD (2013), and 5,977 USD (2014).
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; WHO, World
Health Organization; CEA, cost-effectiveness analysis. Sensitivity 1: 0.95 for healthy, 0.58 for
influenza treated in outpatient department, and 0.58 for influenza treated in inpatient
department (Tarride et al.)[24]. Sensitivity 2: 0.87 for healthy 0.52 for influenza treated in
outpatient department, and 0.05 for influenza treated in inpatient department (Perlroth
et al.)[15]. Sensitivity 3: 0.93 for healthy, 0.558 for influenza treated in outpatient department
and inpatient department (Luce et al.)[25]. Sensitivity 4: 0.92 for healthy, 0.659 for influenza
treated in outpatient department, and 0.514 for influenza treated in inpatient department
(Lee et al.)[26]. Sensitivity 5: 0.91 for healthy, 0.59 for influenza treated in outpatient depart-
ment, and 0.44 for influenza treated in inpatient department (average of all utility weights
used).
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